Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rosetta Genomics to Receive U.S. Patent for Oncology Therapeutic

Published: Thursday, February 27, 2014
Last Updated: Thursday, February 27, 2014
Bookmark and Share
Company receives a Notice of Allowance from the USPTO for a patent claiming Mp53-negative cancer patients.

The allowed claims for U.S. Patent Application No. 12/528,690 entitled "Composition and Methods for Modulating Cell Proliferation and Cell Death," cover a core element of Rosetta Genomics' microRNA technology in the development of cancer therapeutics associated with non-small cell lung cancer (NSCLC) in p53-negative patients. The allowed patent application is jointly owned with Yeda, the technology transfer company of the Weizmann Institute of Science in Rehovot, Israel.

The p53 protein is a sequence-specific transcription factor that functions as a major tumor suppressor in mammals. Inactivation of the tumor-suppressor function of p53 is one of the most frequent genetic alterations in human cancer, and close to half of all human tumors carry p53 gene mutations within their cells.

The patent discloses the finding that miR-34a, which is a direct transcriptional target of p53, possesses anti-proliferative and pro-apoptotic activities, thereby contributing to the tumor suppressor effects of activated p53. Overexpression of miR-34a exerts anti-proliferative effects and promotes cell death, whereas inactivation of miR-34a attenuates p53-mediated cell death. Thus, miR-34a is a direct transcriptional target of p53, which may mediate some of the biological effects of this tumor suppressor. Perturbation of miR-34a expression may thus contribute to tumorigenesis.

"We continue to fortify our leading intellectual property position in microRNA technology and these newly allowed patent claims expand, strengthen and complement our growing portfolio of over 35 patents worldwide," noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "This patent is important as it protects key elements of our microRNA technology to develop oncology treatments for NSCLC in p53 negative patients and offers opportunities for monetization. With RNA-based therapeutics, including microRNA-targeting agents, continuing to progress in and towards the clinic, this patent allowance should create opportunities for us to exploit this important new piece of intellectual property. It also supports our broader oncology strategy to develop and commercialize microRNA-based diagnostics, therapeutics and biomarkers that will enhance clinicians' ability to identify and treat cancers."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rosetta Genomics, Rhenium Collaborate
Collaboration aims to distribute RosettaGx Reveal thyroid cancer diagnostic in Israel.
Friday, September 30, 2016
Rosetta Genomics Receives Approval from New York State
Company has received approval from the NY State for HEME FISH-based tests for detection of amplifications or rearrangements of DNA in a number of hematologic cancers.
Saturday, June 25, 2016
Rosetta Receives Approval from NY State for Four PCR-Based Assays
BRAF, EGFR, KRAS and NRAS mutation detection assays now available in all 50 states.
Tuesday, May 24, 2016
Rosetta Receives Approval for RosettaGX Reveal™
Company has announced conditional approval status for RosettaGX Reveal™, its novel microRNA classifier for the diagnosis of indeterminate thyroid fine needle aspirate.
Friday, March 04, 2016
Rosetta Receives Approval for Cancer Diagnostic
Conditional approval makes RosettaGX Reveal™ available in all 50 states.
Friday, February 19, 2016
Rosetta Genomics to Acquire PersonalizeDx
Rosetta will gain proprietary tests in prostate, bladder and lung cancer.
Monday, April 13, 2015
Rosetta Genomics and Moffitt Cancer Center Enter into Strategic Alliance
Leverages strengths of both organizations to develop diagnostic assays for important, unmet needs in cancer.
Friday, September 05, 2014
Rosetta Genomics Expands Management Team
Brings extensive track record in leading commercial teams and driving revenues in microRNA, oncology and thyroid diagnostics.
Tuesday, August 26, 2014
Rosetta Genomics, Moffitt Cancer Center Enter mRNA-Based Cancer Diagnostic Agreement
Partnership to advance the development and commercialization of Rosetta's thyroid neoplasia assay.
Tuesday, June 10, 2014
Rosetta Genomics Appoints Kevin Watson
Recognized expert in healthcare policy and reimbursement to lead payer efforts for Company's line of microRNA diagnostics.
Thursday, February 20, 2014
Rosetta Genomics Executes Credentialing Agreements With Two National Healthcare Preferred Provider Networks
Adds approximately 44 million potential covered lives for the Rosetta Cancer Origin Test.
Monday, September 09, 2013
Study Validating miRview Lung Assay Published in Journal of Molecular Diagnostics
Assay shown to accurately differentiate between the four main types of lung cancer.
Wednesday, July 11, 2012
Rosetta Genomics Announces Compliance with Continued Listing Requirements of The NASDAQ Capital Market
Company is in compliance with the $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market®.
Thursday, June 07, 2012
Rosetta to Raise $2.2 Million in Registered Direct Offering
Company has entered into agreements with investors to purchase an aggregate of 632,057 ordinary shares at a price of $3.50 per share.
Friday, May 18, 2012
Rosetta Announces $1.75 Million Debt Financing and Potential $1.25 Million Licensing Transaction
Pursuant to the terms of the transaction, Rosetta has also agreed to negotiate in good faith a definitive license agreement with a designee of the holders of the debentures.
Friday, January 27, 2012
Scientific News
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
New Diagnostic Tool for Familial Mediterranean Fever
A new tool developed by researchers at VIB and Ghent University could improve the process of diagnosing Familial Mediterranean Fever.
'Lab on the Skin' for Sweat Analysis
Northwestern University researchers develop a low-cost wearable electronic device that collects and analyzes sweat for health monitoring.
Molecular Signature for Aggressive Brain Tumor Uncovered
Researchers have identified genetic mutations in a highly agressive brain cancer that distinguishes the agressive, from the benign forms of the cancer.
Malaria Parasite Evades Rapid Test Detection in Children
A study at the University of North Carolina found that gene deletion poses a threat to Malaria eradication efforts.
Novel Urine Test to Predict High-Risk Cervical Cancer
Preliminary studies affirm accuracy and potential cost savings to screen for virus-caused malignancy.
GFC Diagnostics Wins Longitude Prize Discovery Award
The global award was won for the development of a cheap, quick and simple MRSA Test.
Understanding Circulating Tumour Cells
Research team develops new tool to track traveling cancer cells in the bloodstream.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!